Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001564590-20-057466
Filing Date
2020-12-17
Accepted
2020-12-17 16:32:33
Documents
10
Effectiveness Date
2020-12-17

Document Format Files

Seq Description Document Type Size
1 S-8 abio-s8.htm S-8 173723
2 EX-5.1 abio-ex51_39.htm EX-5.1 9987
3 EX-23.2 abio-ex232_6.htm EX-23.2 3564
4 GRAPHIC g23gjhpzhlcs000001.jpg GRAPHIC 639
5 GRAPHIC g23gjhpzhlcs000006.jpg GRAPHIC 637
6 GRAPHIC g23gjhpzhlcs000005.jpg GRAPHIC 781
7 GRAPHIC g23gjhpzhlcs000002.jpg GRAPHIC 639
8 GRAPHIC g23gjhpzhlcs000003.jpg GRAPHIC 639
9 GRAPHIC g23gjhpzhlcs000004.jpg GRAPHIC 639
10 GRAPHIC g25kcdflqaux000001.jpg GRAPHIC 3000
  Complete submission text file 0001564590-20-057466.txt   199189
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-251424 | Film No.: 201396486
SIC: 2835 In Vitro & In Vivo Diagnostic Substances